NovoCure (FRA:038) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:038 NovoCure Ltd FRA:038
70 GF Score
Price €14.59
GF Value €15.08
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is NovoCure Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of NovoCure is: High Risk: High uncertainty with risk-return tradeoff.

NovoCure  (FRA:038) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

NovoCure Risk Assessment Related Terms

FRA:038 vs NEOG, AXGN, UFPT: Risk Assessment Comparison

For the Medical Devices subindustry, NovoCure's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Risk Assessment distribution charts can be found below:

* The bar in red indicates where NovoCure's Risk Assessment falls into.


FRA:038
70GF Score
NovoCure Ltd FRA:038
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NovoCure (FRA:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €14.59 is trading 3.2% below its estimated GF Value™ of €15.08. GuruFocus considers NovoCure to be Fairly Valued.

Key valuation signals for FRA:038:

  • Risk Assessment:
  • GF Value™: €15.08 vs. price of €14.59 (3.2% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the FRA:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score

Get the complete analysis for FRA:038

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.59
Price
€15.08
GF Value